CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS), innovators in the treatment of pain and immuno-inflammatory disease, today announced that it has been awarded a $244,000 grant under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grant, which targets therapeutic discovery projects that show potential to result in new therapies to treat areas of unmet medical need or treat chronic or acute diseases and conditions potentially resulting in reduced health care costs, was awarded to Zalicus to help fund the further clinical development of Synavive™, a clinical-stage product candidate in development for immuno-inflammatory diseases such as rheumatoid arthritis.
